Myra L. Patchen

2.6k total citations
80 papers, 2.2k citations indexed

About

Myra L. Patchen is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Myra L. Patchen has authored 80 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Radiology, Nuclear Medicine and Imaging, 20 papers in Oncology and 19 papers in Molecular Biology. Recurrent topics in Myra L. Patchen's work include Effects of Radiation Exposure (28 papers), Hematopoietic Stem Cell Transplantation (12 papers) and Wound Healing and Treatments (8 papers). Myra L. Patchen is often cited by papers focused on Effects of Radiation Exposure (28 papers), Hematopoietic Stem Cell Transplantation (12 papers) and Wound Healing and Treatments (8 papers). Myra L. Patchen collaborates with scholars based in United States, Germany and Philippines. Myra L. Patchen's co-authors include Thomas J. MacVittie, Ryuji Ueno, L M Souza, T J MacVittie, Michele Gargano, Thomas L. Walden, Liying Yang, Barthel Barlogie, Benjamin Drewinko and Danuta H. Malinowska and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and PLoS ONE.

In The Last Decade

Myra L. Patchen

80 papers receiving 2.0k citations

Peers

Countries citing papers authored by Myra L. Patchen

Since Specialization

Citations

This map shows the geographic impact of Myra L. Patchen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Myra L. Patchen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Myra L. Patchen more than expected).

Fields of papers citing papers by Myra L. Patchen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Myra L. Patchen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Myra L. Patchen. The network helps show where Myra L. Patchen may publish in the future.

Co-authorship network of co-authors of Myra L. Patchen

This figure shows the co-authorship network connecting the top 25 collaborators of Myra L. Patchen. A scholar is included among the top collaborators of Myra L. Patchen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Myra L. Patchen. Myra L. Patchen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Inhibitory affinity modulation of FcγRIIA ligand binding by glycosphingolipids by inside-out signaling 2021 ·Cell Reports ·Koshu Okubo, Michael D. Brenner, Xavier Culleré, Gurpanna Saggu, Myra L. Patchen, Nandita Bose, (unknown), Zhou Yuan, Clifford A. Lowell, Cheng Zhu, Tanya N. Mayadas	5
2	A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer 2017 ·Investigational New Drugs ·Michael Thomas, Parvis Sadjadian, Jens Kollmeier, (unknown), (unknown), J. Richard Trout, Michele Gargano, Myra L. Patchen, Richard M. Walsh, Martin Béliveau, Jean‐Francois Marier, Nandita Bose, Keith Gorden, Folker Schneller	46
3	Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation 2016 ·PLoS ONE ·Anissa Chan, (unknown), Xiaohong Qiu, (unknown), Richard M. Walsh, Keith Gorden, (unknown), Peter Maimonis, Steven Leonardo, (unknown), Michael E. Danielson, (unknown), (unknown), Jeremy R. Graff, Myra L. Patchen, Nandita Bose	37
4	Efficacy and Safety of Imprime Pgg, a Novel Innate Immune Modulator, in Combination with Bevacizumab (BEV), Carboplatin and Paclitaxel for the 1St-Line Treatment of Stage Iv Nsclc 2015 ·Annals of Oncology ·Ada Braun, Walburga Engel-Riedel, Folker Schneller, M. Wolf, Wolfgang Schuette, (unknown), (unknown), Michele Gargano, Myra L. Patchen, Richard D. Huhn	2
5	Binding of Soluble Yeast β-Glucan to Human Neutrophils and Monocytes is Complement-Dependent 2013 ·Frontiers in Immunology ·Nandita Bose, Anissa Chan, (unknown), (unknown), Xiaohong Qiu, Richard M. Walsh, (unknown), (unknown), Keith Gorden, (unknown), (unknown), Michael E. Danielson, (unknown), Andrew S. Magee, Myra L. Patchen, John P. Vasilakos	55
6	The Polysaccharide, PGG-Glucan, Enhances Human Myelopoiesis by Direct Action Independent of and Additive to Early-Acting Cytokines 1999 ·Acta Haematologica ·(unknown), Myra L. Patchen, David T. Scadden	27
7	Enhanced clearance of a multiple antibiotic resistant Staphylococcus aureus in rats treated with PGG-glucan is associated with increased leukocyte counts and increased neutrophil oxidative burst activity 1998 ·International Journal of Immunopharmacology ·Jinsheng Liang, D. Melican, (unknown), Gerard P. Palace, (unknown), Robert Armstrong, Myra L. Patchen	112
8	Effects of particulate and soluble (1–3)-β-glucans on Ca2+ influx in NR8383 alveolar macrophages 1998 ·Immunopharmacology ·Ann‐Christin Mörk, Ronald J. Helmke, J. Ricardo Martinez, (unknown), Myra L. Patchen, (unknown)	10
9	Sublethal Gamma Irradiation Increases IL-lα, IL-6, and TNF-α mRNA Levels in Murine Hematopoietic Tissues 1997 ·Journal of Interferon & Cytokine Research ·(unknown), Alex Limanni, William H. Baker, Michael E. Dobson, John F. Kalinich, Myra L. Patchen	32
10	Ulstrastructural localization of tumour necrosis factor-alpha 1994 ·The Histochemical Journal ·(unknown), Stephen P. Chock, Myra L. Patchen	25
11	Histopathologic Effects of Soluble Glucan and WR-2721, Independently and Combined in C3H/HeN Mice 1992 ·Experimental Biology and Medicine ·William H. Baker, James B. Nold, Myra L. Patchen, William E. Jackson	8
12	Postirradiation treatment with granulocyte colony-stimulating factor and preirradiation WR-2721 administration synergize to enhance hemopoietic reconstitution and increase survival 1992 ·International Journal of Radiation OncologyBiologyPhysics ·Myra L. Patchen, Thomas J. MacVittie, L M Souza	56
13	Radioprotection by selenium compounds 1992 ·Biological Trace Element Research ·Joseph F. Weiss, V. Srinivasan, K. Sree Kumar, Myra L. Patchen, Michael R. Landauer	7
14	Combined modality radioprotection: The use of glucan and selenium with WR-2721 1990 ·International Journal of Radiation OncologyBiologyPhysics ·Myra L. Patchen, Thomas J. MacVittie, Joseph F. Weiss	43
15	Therapeutic Use of Recombinant Human G-CSF (rhG-CSF) in a Canine Model of Sublethal and Lethal Whole-body Irradiation 1990 ·International Journal of Radiation Biology ·Thomas J. MacVittie, Rodney L. Monroy, Myra L. Patchen, L M Souza	101
16	Glucan enhances survival in an intraabdominal infection model 1989 ·Journal of Surgical Research ·(unknown), Myra L. Patchen, Thomas J. MacVittie, Erwin F. Hirsch, Mitchell P. Fink	14
17	Survey of newer biological response modifiers for possible use in radioprotection 1988 ·Pharmacology & Therapeutics ·Michael A. Chirigos, Myra L. Patchen	11
18	Radioprotection by biological response modifiers alone and in combination with WR-2721 1988 ·Pharmacology & Therapeutics ·Myra L. Patchen, (unknown), Michael A. Chirigos, Joseph F. Weiss	22
19	Enhanced Hematopoietic Recovery in Irradiated Mice Pretreated with Interleukin-1 (IL-1) 1987 ·Immunopharmacology and Immunotoxicology ·Gretchen N. Schwartz, T J MacVittie, R. M. Vigneulle, Myra L. Patchen, S Douches, Joost J. Oppenheim, R Neta	33
20	Comparative effects of soluble and particulate glucans on survival in irradiated mice. 1986 ·PubMed ·Myra L. Patchen, Thomas J. MacVittie	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact